{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:29:43Z","timestamp":1791944983613,"version":"4.3.4"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Therapeutic drug monitoring for mycophenolic acid (MPA) is challenging due to difficulties in measuring the area under the curve (AUC). Limited sampling strategies (LSSs) have been developed for MPA therapeutic drug monitoring but come with risk of unacceptable performance. The authors hypothesized that the poor predictive performance of LSSs were due to the variability in MPA enterohepatic recirculation (EHR). This study is the first to evaluate LSSs models performance in the context of EHR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Adult kidney transplant recipients (n = 84) receiving oral mycophenolate mofetil underwent intensive MPA pharmacokinetic sampling. MPA AUC<jats:sub>0\u201312hr<\/jats:sub> and EHR were determined. Published MPA LSSs in kidney transplant recipients receiving tacrolimus were evaluated for their predictive performance in estimating AUC<jats:sub>0\u201312hr<\/jats:sub> in our full cohort and separately in individuals with high and low EHR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>None of the evaluated LSS models (n = 12) showed good precision or accuracy in predicting MPA AUC<jats:sub>0\u201312hr<\/jats:sub> in the full cohort. In the high EHR group, models with late timepoints had better accuracy but low precision, except for 1 model with late timepoints at 6 and 10 hours postdose, which had marginally acceptable precision. For all models, the good guess of predicted AUC<jats:sub>0\u201312hr<\/jats:sub> (\u00b115% of observed AUC<jats:sub>0\u201312hr<\/jats:sub>) was highly variable (range, full cohort = 19%\u201361.9%; high EHR = 4.5%\u201365.9%; low EHR = 27.5%\u201362.5%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The predictive performance of the LSS models varied according to EHR status. Timepoints \u22655 hours postdose in LSS models are essential to capture EHR. Models and strategies that incorporate EHR during development are required to accurately ascertain MPA exposure.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001248","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T21:00:40Z","timestamp":1721854840000},"page":"174-182","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Limited Sampling Strategies Fail to Accurately Predict Mycophenolic Acid Area Under the Curve in Kidney Transplant Recipients and the Impact of Enterohepatic Recirculation"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7266-9980","authenticated-orcid":false,"given":"Moataz E.","family":"Mohamed","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Saqr","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Al-Kofahi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota;"},{"name":"Gilead Sciences, Inc., Foster City, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Onyeaghala","sequence":"additional","affiliation":[{"name":"Hennepin Healthcare Research Institute, Minneapolis, Minnesota;"},{"name":"Department of Medicine, School of Medicine, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory P.","family":"Remmel","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Staley","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey R.","family":"Dorr","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota;"},{"name":"Hennepin Healthcare Research Institute, Minneapolis, Minnesota;"},{"name":"Department of Medicine, School of Medicine, University of Minnesota, Minneapolis, Minnesota;"},{"name":"Department of Medicine, Hennepin Healthcare, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levi","family":"Teigen","sequence":"additional","affiliation":[{"name":"Department of Food Science and Nutrition, University of Minnesota, St. Paul, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Guan","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Madden","sequence":"additional","affiliation":[{"name":"Department of Surgery, Clinical Trials Office, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Munoz","sequence":"additional","affiliation":[{"name":"Department of Surgery, Clinical Trials Office, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duy","family":"Vo","sequence":"additional","affiliation":[{"name":"Hennepin Healthcare Research Institute, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Hennepin Healthcare Research Institute, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"El-Rifai","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, School of Medicine, University of Minnesota, Minneapolis; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Oetting","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur J.","family":"Matas","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Israni","sequence":"additional","affiliation":[{"name":"Hennepin Healthcare Research Institute, Minneapolis, Minnesota;"},{"name":"Department of Medicine, Hennepin Healthcare, Minneapolis, Minnesota;"},{"name":"Department of Epidemiology & Community Health, University of Minnesota, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4145-7045","authenticated-orcid":false,"given":"Pamala A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"R1-20250108","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.ajt.2023.02.004","article-title":"OPTN\/SRTR 2021 annual data report: kidney","volume":"23","author":"Lentine","year":"2023","journal-title":"Am J Transpl"},{"key":"R2-20250108","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1015828802490","article-title":"Bioavailability improvement of mycophenolic acid through amino ester derivatization","volume":"7","author":"Lee","year":"1990","journal-title":"Pharm Res"},{"key":"R3-20250108","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"R4-20250108","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/ki.2013.517","article-title":"Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients","volume":"85","author":"Colom","year":"2014","journal-title":"Kidney Int"},{"key":"R5-20250108","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1034\/j.1600-6143.2003.00079.x","article-title":"Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies","volume":"3","author":"Shaw","year":"2003","journal-title":"Am J Transpl"},{"key":"R6-20250108","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/j.1552-4604.2000.tb05988.x","article-title":"Mycophenolic acid area under the curve values in African American and caucasian renal transplant patients are comparable","volume":"40","author":"Shaw","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"R7-20250108","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","article-title":"Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"43","author":"Bergan","year":"2021","journal-title":"Ther Drug Monit"},{"key":"R8-20250108","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2215\/CJN.05440610","article-title":"Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring","volume":"6","author":"De Winter","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R9-20250108","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/TP.0b013e3181744199","article-title":"Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review","volume":"85","author":"Knight","year":"2008","journal-title":"Transplantation"},{"key":"R10-20250108","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trre.2011.01.002","article-title":"Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of the transplantation society consensus meeting","volume":"25","author":"Le Meur","year":"2011","journal-title":"Transpl Rev"},{"key":"R11-20250108","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/TP.0b013e318186f98a","article-title":"Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial","volume":"86","author":"Van Gelder","year":"2008","journal-title":"Transplantation"},{"key":"R37-20250108","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.1600-6143.2009.02668.x","article-title":"Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the opticept trial","volume":"9","author":"Gaston","year":"2009","journal-title":"Am J Transpl"},{"key":"R12-20250108","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","article-title":"Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation","volume":"7","author":"Le Meur","year":"2007","journal-title":"Am J Transpl"},{"key":"R13-20250108","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/TP.0b013e3181e06584","article-title":"Evaluation of the mycophenolic acid exposure estimation methods used in the APOMYGERE, FDCC, and opticept trials","volume":"90","author":"Barraclough","year":"2010","journal-title":"Transplantation"},{"key":"R14-20250108","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.ftd.0000211810.19935.44","article-title":"Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants","volume":"28","author":"Ting","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R15-20250108","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/FTD.0b013e31820f40f8","article-title":"Optimal sampling strategy development methodology using maximum a posteriori bayesian estimation","volume":"33","author":"Van Der Meer","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R16-20250108","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1517\/17425255.2016.1170806","article-title":"Therapeutic drug monitoring of mycophenolate in adult solid organ transplant patients: an update","volume":"12","author":"Kiang","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R17-20250108","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s13318-021-00713-0","article-title":"A systematic review of multiple linear regression-based limited sampling strategies for mycophenolic acid area under the concentration\u2013time curve estimation","volume":"46","author":"Sobiak","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R18-20250108","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/jcph.1064","article-title":"Mycophenolic acid and its metabolites in kidney transplant recipients: a semimechanistic enterohepatic circulation model to improve estimating exposure","volume":"58","author":"Okour","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"R19-20250108","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2125.2007.02934.x","article-title":"Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients","volume":"64","author":"Pescovitz","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"R20-20250108","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1111\/j.1600-6143.2005.01107.x","article-title":"Influence of Co\u2010medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation","volume":"5","author":"Cattaneo","year":"2005","journal-title":"Am J Transpl"},{"key":"R21-20250108","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bcpt.13743","article-title":"Pharmacokinetics of free and total mycophenolic acid in paediatric and adult renal transplant recipients: exploratory analysis of the effects of clinical factors and gene variants","volume":"131","author":"Liu","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R22-20250108","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/FTD.0b013e31818b8244","article-title":"Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation","volume":"30","author":"Mino","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R23-20250108","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1177\/0091270009335003","article-title":"Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients","volume":"49","author":"Naito","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"R24-20250108","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e3181ae44b9","article-title":"Early phase limited sampling strategy characterizing tacrolimus and mycophenolic acid pharmacokinetics adapted to the maintenance phase of renal transplant patients","volume":"31","author":"Miura","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R25-20250108","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1078155220980815","article-title":"Pharmacokinetics of mycophenolic acid after haplo-hematopoietic stem cell transplantation in Japanese recipients","volume":"28","author":"Uchiyama","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"R26-20250108","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/cts.13495","article-title":"Age associations with tacrolimus and mycophenolic acid pharmacokinetics in stable black and white kidney transplant recipients: implications for Health inequities","volume":"16","author":"Tornatore","year":"2023","journal-title":"Clin Transl Sci"},{"key":"R27-20250108","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/jcph.125","article-title":"Limited sampling strategy of mycophenolic acid in adult kidney transplant recipients: influence of the post-transplant period and the pharmacokinetic profile","volume":"53","author":"Chaabane","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"R45-20250108","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"R29-20250108","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/clinchem\/48.9.1497","article-title":"Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus","volume":"48","author":"Pawinski","year":"2002","journal-title":"Clin Chem"},{"key":"R46-20250108","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1016\/S0041-1345(03)00762-0","article-title":"The Influence of Calcineurin Inhibitors on Mycophenolic Acid Pharmacokinetics","volume":"35","author":"Kuriata-Kordek","year":"2003","journal-title":"Transplant Proc"},{"key":"R40-20250108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5649\/jjphcs.30.1","article-title":"Limited sampling strategy for estimating area under the concentration curve for mycophenolic acid in renal transplant recipients with Co-administration of tacrolimus","volume":"30","author":"Toda","year":"2004","journal-title":"Iryo Yakugaku (Japanese J Pharm Health Care Sciences)"},{"key":"R47-20250108","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2710.2008.00896.x","article-title":"Estimation of the area under the curve for mycophenolic acid in adult renal transplant patients with concomitant tacrolimus using a limited sampling strategy","volume":"33","author":"Teshima","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"R38-20250108","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/FTD.0b013e31815f5416","article-title":"Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients","volume":"30","author":"Miura","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R39-20250108","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/FTD.0b013e3182028b23","article-title":"Development and validation of limited sampling strategies for tacrolimus and mycophenolate in steroid-free renal transplant regimens","volume":"33","author":"Poulin","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R41-20250108","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1440-1797.2011.01560.x","article-title":"A limited sampling strategy for the simultaneous estimation of tacrolimus, mycophenolic acid and unbound prednisolone exposure in adult kidney transplant recipients","volume":"17","author":"Barraclough","year":"2012","journal-title":"Nephrology"},{"key":"R28-20250108","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/FTD.0000000000000165","article-title":"Limited sampling strategy for predicting area under the concentration-time curve for mycophenolic acid in Chinese adults receiving mycophenolate mofetil and tacrolimus early after renal transplantation","volume":"37","author":"Cai","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R48-20250108","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.transproceed.2018.02.068","article-title":"Limited sampling strategy for estimating mycophenolic acid exposure on day 7 post-transplant for two mycophenolate Mofetil formulations derived from 20 Chinese renal transplant recipients","volume":"50","author":"Cai","year":"2018","journal-title":"Transplant Proc"},{"key":"R30-20250108","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/FTD.0b013e31819c077c","article-title":"Comparison of 3 estimation methods of mycophenolic acid auc based on a limited sampling strategy in renal transplant patients","volume":"31","author":"Hulin","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R31-20250108","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/bcp.12007","article-title":"Statistical tools for dose individualization of mycophenolic acid and tacrolimus Co-administered during the first month after renal transplantation","volume":"75","author":"Musuamba","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"R32-20250108","doi-asserted-by":"crossref","first-page":"859351","DOI":"10.3389\/fphar.2022.859351","article-title":"Population pharmacokinetics of mycophenolic acid in renal transplant patients: a comparison of the early and stable posttransplant stages","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"R33-20250108","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/FTD.0000000000001020","article-title":"Estimation of mycophenolic acid exposure in Chinese renal transplant patients by a joint deep learning model","volume":"44","author":"Shao","year":"2022","journal-title":"Ther Drug Monit"},{"key":"R35-20250108","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/01.ftd.0000162231.90811.38","article-title":"Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods","volume":"27","author":"Pr\u00e9maud","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R36-20250108","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/FTD.0b013e3181fc8fbb","article-title":"Evaluation of limited sampling strategies for mycophenolic acid after mycophenolate mofetil intake in adult kidney transplant recipients","volume":"32","author":"Barraclough","year":"2010","journal-title":"Ther Drug Monit"},{"key":"R42-20250108","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1517\/17425250903114182","article-title":"Limited sampling strategies for mycophenolic acid in solid organ transplantation: a systematic review","volume":"5","author":"Bruchet","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R43-20250108","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s40262-021-01037-7","article-title":"The impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of mycophenolic acid: systematic review and meta-analysis","volume":"60","author":"Na Takuathung","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"R44-20250108","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/bs.acc.2016.04.001","article-title":"Therapeutic drug monitoring of mycophenolic acid","volume":"76","author":"Dasgupta","year":"2016","journal-title":"Adv Clin Chem"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:00:58Z","timestamp":1736348458000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001248","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"2024-04-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}